Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

Coagulation factor VA2440G causes east Texas bleeding disorder via TFPIα
Lisa M. Vincent, … , Dianna M. Milewicz, Björn Dahlbäck
Lisa M. Vincent, … , Dianna M. Milewicz, Björn Dahlbäck
Published August 27, 2013
Citation Information: J Clin Invest. 2013;123(9):3777-3787. https://doi.org/10.1172/JCI69091.
View: Text | PDF
Research Article Article has an altmetric score of 51

Coagulation factor VA2440G causes east Texas bleeding disorder via TFPIα

  • Text
  • PDF
Abstract

The autosomal dominantly inherited east Texas bleeding disorder is linked to an A2440G variant in exon 13 of the F5 gene. Affected individuals have normal levels of coagulation factor V (FV) activity, but demonstrate inhibition of global coagulation tests. We demonstrated that the A2440G mutation causes upregulation of an alternatively spliced F5 transcript that results in an in-frame deletion of 702 amino acids of the large activation fragment, the B domain. The approximately 250-kDa FV isoform (FV-short), which can be fully activated by thrombin, is present in all A2440G carriers’ plasma (n = 16). FV-short inhibits coagulation through an indirect mechanism by forming a complex with tissue factor pathway inhibitor-α (TFPIα), resulting in an approximately 10-fold increase in plasma TFPIα, suggesting that the TFPIα:FV-short complexes are retained in circulation. The TFPIα:FV-short complexes efficiently inhibit thrombin generation of both intrinsic and extrinsic coagulation pathways. These data demonstrate that the east Texas bleeding disorder–associated F5A2440G leads to the formation of the TFPIα:FV-short complex, which inhibits activation and propagation of coagulation.

Authors

Lisa M. Vincent, Sinh Tran, Ruzica Livaja, Tracy A. Bensend, Dianna M. Milewicz, Björn Dahlbäck

×

Total citations by year

Year: 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2009 Total
Citations: 5 5 10 11 1 5 4 11 2 3 3 2 1 63
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article (63)

Title and authors Publication Year
Factor V variants in bleeding and thrombosis
Mohapatra AK, Todaro AM, Castoldi E
Research and Practice in Thrombosis and Haemostasis 2024
Tissue factor pathway inhibitor – cofactor-dependent regulation of the initiation of coagulation
Ahnström J, Petri A, Crawley JT
Current Opinion in Hematology 2024
The Prothrombin-Prothrombinase Interaction.
Stojanovski BM, Mohammed BM, Di Cera E
Sub-cellular biochemistry 2024
The common VTE-protective G haplotype of F5 increases factor V-short, TFPI function, and risk of bleeding
Sims MC, Gierula M, Stephens JC, Tokolyi A, Stefanucci L, Persyn E, Sun L, Collins JH, Davenport EE, Di Angelantonio E, Downes K, Inouye M, Paul DS, Thomas W, Tolios A, Ouwehand WH, Gleadall NS, Crawley JT, Butterworth AS, Frontini M, Ahnström J
Blood Advances 2024
TFPIα anticoagulant function is highly dependent on protein S in vivo
Petri A, Sasikumar P, Folgado PB, Jones D, Xu Y, Ahnström J, Salles-Crawley II, Crawley JT
Science Advances 2024
Impaired factor V–related anticoagulant mechanisms and deep vein thrombosis associated with A2086D and W1920R mutations
Shimonishi N, Ogiwara K, Yoshida J, Horie K, Nakajima Y, Furukawa S, Takeyama M, Nogami K
Blood Advances 2023
Post-transcriptional control of haemostatic genes: mechanisms and emerging therapeutic concepts in thrombo-inflammatory disorders
Danckwardt S, Trégouët DA, Castoldi E
Cardiovascular Research 2023
Cryo-EM structure of coagulation factor V short
Mohammed BM, Pelc LA, Rau MJ, Di Cera E
Blood 2023
Investigating patients for bleeding disorders when most of the “usual” ones have been ruled out
Mehic D, Pabinger I, Gebhart J
Research and Practice in Thrombosis and Haemostasis 2023
Structural architecture of the acidic region of the B domain of coagulation factor V.
Mohammed BM, Basore K, Summers B, Pelc LA, Di Cera E, Mohammed BM, Basore K, Summers B, Pelc LA, Di Cera E
Journal of Thrombosis and Haemostasis 2023
Laminin G1 residues of protein S mediate its TFPI cofactor function and are competitively regulated by C4BP
A Teraz-Orosz, M Gierula, A Petri, D Jones, R Keniyopoullos, P Folgado, S Santamaria, J Crawley, D Lane, J Ahnström
Blood Advances 2022
Thrombin generation measured on ST Genesia, a new platform in the coagulation routine lab: Assessment of analytical and between‐subject variation
S Kristensen, J Nybo, S Pedersen
Research and Practice in Thrombosis and Haemostasis 2022
Coagulation Factor V is a T cell inhibitor expressed by leukocytes in COVID-19
J Wang, P Kotagiri, P Lyons, R Al-Lamki, F Mescia, L Bergamaschi, L Turner, M Morgan, F Calero-Nieto, K Bach, N Mende, N Wilson, E Watts, P Maxwell, P Chinnery, N Kingston, S Papadia, K Stirrups, N Walker, R Gupta, D Menon, K Allinson, S Aitken, M Toshner, M Weekes, J Nathan, S Walmsley, W Ouwehand, M Kasanicki, B Göttgens, J Marioni, K Smith, J Pober, J Bradley
iScience 2022
A hydrophobic patch (PLVIVG; 1481–1486) in the B‐domain of factor V‐short is crucial for its synergistic TFPIα‐cofactor activity with protein S and for the formation of the FXa‐inhibitory complex comprising FV‐short, TFPIα, and protein S
Dahlbäck B, Tran S
Journal of Thrombosis and Haemostasis 2022
Regulation of coagulation by tissue factor pathway inhibitor: Implications for hemophilia therapy.
Mast AE, Ruf W
Journal of Thrombosis and Haemostasis 2022
Cryo‐EM structures of coagulation factors
Di Cera E, Mohammed BM, Pelc LA, Stojanovski BM
Research and Practice in Thrombosis and Haemostasis 2022
Regulation of factor V by the anticoagulant protease activated protein C: Influence of the B-domain and TFPIα
Ayombil F, Petrillo T, Kim H, Camire RM
The Journal of biological chemistry 2022
Inhibition of platelet-surface-bound proteins during coagulation under flow I: TFPI
Miyazawa K, Fogelson AL, Leiderman K
Biophysical Journal 2022
Tissue factor pathway inhibitor is a potential modifier of bleeding risk in factor XI deficiency.
Reitsma SE, Holle LA, Bouck EG, Monroe DM, Mast AE, Burthem J, Bolton-Maggs PHB, Gidley GN, Wolberg AS
Journal of Thrombosis and Haemostasis 2022
Platelet tissue factor pathway inhibitor-α dampens cardiac thrombosis and associated fibrosis in mice
Maroney SA, Siebert AE, Martinez ND, Rasmussen M, Peterson JA, Weiler H, Lincoln J, Mast AE
Journal of Thrombosis and Haemostasis 2022
Regulation of factor V and factor V-short by TFPIα: Relationship between B-domain proteolysis and binding
T Petrillo, F Ayombil, C vant Veer, RM Camire
The Journal of biological chemistry 2021
Elevated levels of tissue factor pathway inhibitor in patients with mild to moderate bleeding tendency
D Mehic, A Tolios, S Hofer, C Ay, H Haslacher, J Rejtö, WH Ouwehand, K Downes, M Haimel, I Pabinger, J Gebhart
Blood Advances 2021
Major Reservoir for Heparin-Releasable TFPIα (Tissue Factor Pathway Inhibitor α) Is Extracellular Matrix
JA Peterson, SA Maroney, ND Martinez, AE Mast
Arteriosclerosis, thrombosis, and vascular biology 2021
Insights into the Functional Role of ADTRP (Androgen-Dependent TFPI-Regulating Protein) in Health and Disease
C Lupu, MM Patel, F Lupu
International journal of molecular sciences 2021
Cryo-EM structures of human coagulation factors V and Va
EA Ruben, MJ Rau, JA Fitzpatrick, ED Cera
Blood 2021
Natural anticoagulants: A missing link in mild to moderate bleeding tendencies
D Mehic, M Colling, I Pabinger, J Gebhart
Haemophilia : the official journal of the World Federation of Hemophilia 2021
The contribution of TFPIα to the hemostatic response to injury in mice
TT Marar, ND Martinez, SA Maroney, AE Siebert, J Wu, TJ Stalker, M Tomaiuolo, S Delacroix, RD Simari, AE Mast, LF Brass
Journal of Thrombosis and Haemostasis 2021
U5 snRNA Interactions With Exons Ensure Splicing Precision
OV Artemyeva-Isman, AC Porter
Frontiers in Genetics 2021
F5 ‐Atlanta: Factor V‐short strikes again
E Castoldi
Journal of Thrombosis and Haemostasis 2021
Factor V east Texas variant causes bleeding in a three‐generation family
J Peterson, S Gupta, N Martinez, B Hardesty, S Maroney, A Mast
Journal of Thrombosis and Haemostasis 2021
Major bleeding during oral anticoagulant therapy associated with factor V activation by factor Xa
Maag A, van Rein N, Schuijt TJ, Kopatz WF, Kruijswijk D, Thomassen S, Hackeng TM, Camire RM, van der Poll T, Meijers JC, Bos MH, van \u2019t Veer C
Journal of Thrombosis and Haemostasis 2021
Platelet anticoagulant proteins: Modulators of thrombosis propensity within a procoagulant cell
AE Siebert, AE Mast
Journal of Thrombosis and Haemostasis 2020
Minor allele of the factor V K858R variant protects from venous thrombosis only in non-carriers of factor V Leiden mutation
M Ibrahim-Kosta, P Suchon, F Couturaud, D Smadja, R Olaso, M Germain, N Saut, L Goumidi, C Derbois, F Thibord, S Debette, P Amouyel, JF Deleuze, P van Doorn, E Castoldi, E Patin, MC Alessi, DA Trégouët, PE Morange
Scientific Reports 2019
Thrombin‐generating potential, plasma clot formation, and clot lysis are impaired in patients with bleeding of unknown cause
S Hofer, C Ay, J Rejtö, AS Wolberg, H Haslacher, S Koder, I Pabinger, J Gebhart
Journal of Thrombosis and Haemostasis 2019
Tissue factor pathway inhibitor primes monocytes for antiphospholipid antibody-induced thrombosis
N Müller-Calleja, A Hollerbach, S Ritter, DG Pedrosa, D Strand, C Graf, C Reinhardt, S Strand, P Poncelet, JH Griffin, KJ Lackner, W Ruf
Blood 2019
Measurement of plasma and platelet tissue factor pathway inhibitor, factor V and Protein S in people with haemophilia
PE Ellery, I Hilden, P Thyregod, ND Martinez, SA Maroney, JC Gill, AE Mast
Haemophilia : the official journal of the World Federation of Hemophilia 2019
Fundamentals for a Systematic Approach to Mild and Moderate Inherited Bleeding Disorders: An EHA Consensus Report
F Rodeghiero, I Pabinger, M Ragni, R Abdul-Kadir, E Berntorp, V Blanchette, I Bodó, A Casini, P Gresele, R Lassila, F Leebeek, D Lillicrap, D Mezzano, P Noris, A Srivastava, A Tosetto, J Windyga, B Zieger, M Makris, N Key
HemaSphere 2019
A synthesis approach of mouse studies to identify genes and proteins in arterial thrombosis and bleeding
CC Baaten, S Meacham, SM de Witt, MA Feijge, DJ Adams, JW Akkerman, JM Cosemans, L Grassi, S Jupe, M Kostadima, NJ Mattheij, MH Prins, R Ramirez-Solis, O Soehnlein, F Swieringa, C Weber, JK White, WH Ouwehand, JW Heemskerk
Blood 2018
Factor V levels and risk of venous thrombosis: The MEGA case-control study
IM Rietveld, MH Bos, WM Lijfering, R Li-Gao, FR Rosendaal, PH Reitsma, SC Cannegieter
Research and Practice in Thrombosis and Haemostasis 2018
Coagulation factor V gene 1691G>A polymorphism as an indicator for risk and prognosis of lower extremity deep venous thrombosis in Chinese Han population:
CL Zhang, ZM Li, ZH Song, T Song
Medicine 2018
Suppressive Role of Tissue Factor Pathway Inhibitor-α in Platelet-Dependent Fibrin Formation under Flow Is Restricted to Low Procoagulant Strength
S Thomassen, T Mastenbroek, F Swieringa, K Winckers, M Feijge, R Schrijver, J Cosemans, S Maroney, A Mast, T Hackeng, J Heemskerk
Thrombosis and Haemostasis 2018
Factor V-short and protein S as synergistic tissue factor pathway inhibitor (TFPIα) cofactors
B Dahlbäck, LJ Guo, R Livaja-Koshiar, S Tran
Research and Practice in Thrombosis and Haemostasis 2017
Correlates of plasma and platelet tissue factor pathway inhibitor, factor V, and Protein S
PE Ellery, I Hilden, K Sejling, M Loftager, ND Martinez, SA Maroney, AE Mast
Research and Practice in Thrombosis and Haemostasis 2017
Selective factor VIII activation by the tissue factor-factor VIIa-factor Xa complex
Y Kamikubo, GL Mendolicchio, A Zampolli, P Marchese, AS Rothmeier, JN Orje, AJ Gale, S Krishnaswamy, A Gruber, H Østergaard, LC Petersen, W Ruf, ZM Ruggeri
Blood 2017
Reduced prothrombinase inhibition by tissue factor pathway inhibitor contributes to the factor V Leiden hypercoagulable state
JP Wood, LM Kreuziger, PE Ellery, SA Maroney, AE Mast
Blood Advances 2017
New clotting disorders that cast new light on blood coagulation and may play a role in clinical practice
A Girolami, E Cosi, S Ferrari, AM Lombardi, B Girolami
Journal of Thrombosis and Thrombolysis 2017
Factor V has an anticoagulant cofactor activity that targets the early phase of coagulation
S Santamaria, N Reglińska-Matveyev, M Gierula, RM Camire, JT Crawley, DA Lane, J Ahnström
The Journal of biological chemistry 2017
Thrombotic and Hemorrhagic Conditions Due to a Gain of Function of Coagulation Proteins: A Special Type of Clotting Disorders
A Girolami, E Cosi, S Ferrari, A Lombardi, F Fabris
Clinical and Applied Thrombosis/Hemostasis 2017
Heparin, coumarin, protein C, antithrombin, fibrinolysis and other clotting related resistances: old and new concepts in blood coagulation
A Girolami, E Cosi, S Ferrari, B Girolami
Journal of Thrombosis and Thrombolysis 2017
TFPIα interacts with FVa and FXa to inhibit prothrombinase during the initiation of coagulation
Jeremy P Wood, Helle H Petersen, Bingke Yu, Xiaoai Wu, Ida Hilden, Alan E Mast
Blood Advances 2017
Elevated Plasma Factor IXa Activity in Premenopausal Women on Hormonal ContraceptionHighlights
P Tanratana, P Ellery, P Westmark, AE Mast, JP Sheehan
Arteriosclerosis, thrombosis, and vascular biology 2017
Prothrombin: Another Clotting Factor After FV That Is Involved Both in Bleeding and Thrombosis
A Girolami, E Cosi, S Ferrari, B Girolami
Clinical and Applied Thrombosis/Hemostasis 2017
The hemostatic role of factor XI
C Puy, RA Rigg, OJ McCarty
Thrombosis Research 2016
Platelet-Derived Short-Chain Polyphosphates Enhance the Inactivation of Tissue Factor Pathway Inhibitor by Activated Coagulation Factor XI
C Puy, EI Tucker, IS Ivanov, D Gailani, SA Smith, JH Morrissey, A Gruber, OJ McCarty, C Schulz
PloS one 2016
New insights into the biology of tissue factor pathway inhibitor
SA Maroney, AE Mast
Journal of Thrombosis and Haemostasis 2015
Tissue Factor Pathway Inhibitor: Multiple Anticoagulant Activities for a Single Protein
AE Mast
Arteriosclerosis, thrombosis, and vascular biology 2015
PlateletsSignificance: Context-Dependent Vascular Protectors or Mediators of Disease
R Westrick, G Fredman
Arteriosclerosis, thrombosis, and vascular biology 2015
Biology of tissue factor pathway inhibitor
JP Wood, PE Ellery, SA Maroney, AE Mast
Blood 2014
Erythrocyte-derived microparticles supporting activated protein C-mediated regulation of blood coagulation
RL Koshiar, S Somajo, E Norström, B Dahlbäck
PloS one 2014
Platelets Contain Tissue Factor Pathway Inhibitor-2 Derived from Megakaryocytes and Inhibits Fibrinolysis
K Vadivel, SM Ponnuraj, Y Kumar, AK Zaiss, MW Bunce, RM Camire, L Wu, D Evseenko, HR Herschman, MS Bajaj, SP Bajaj
The Journal of biological chemistry 2014
Factor V, tissue factor pathway inhibitor, and the East Texas Bleeding Disorder
George Broze, Thomas J. Girard
Journal of Clinical Investigation 2013
Tissue factor pathway inhibitor-alpha inhibits prothrombinase during the initiation of blood coagulation
JP Wood, MW Bunce, SA Maroney, PB Tracy, RM Camire, AE Mast
Proceedings of the National Academy of Sciences 2013
Pulmonary surfactant: an immunological perspective
ZC Chroneos, Z Sever-Chroneos, VL Shepherd
Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 2009

← Previous 1 2 3 Next →

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Picked up by 6 news outlets
Posted by 1 X users
Referenced in 1 patents
On 1 Facebook pages
Referenced in 1 Wikipedia pages
Referenced in 2 clinical guideline sources
61 readers on Mendeley
See more details